Microneedle Sensor Tracks Drug Clearance and Detects Early Kidney and Liver Dysfunction

Powerful medications often require precise dosing, yet clinicians usually rely on occasional blood tests that provide only brief snapshots of how a patient’s body processes a drug. This creates a risk of missing the moment when a dose becomes ineffective or begins to strain the organs responsible for clearing it. A UCLA‑led research team has developed a microneedle sensor designed to solve this problem by continuously monitoring drug levels just beneath the skin. The goal is to give doctors real‑time insight into kidney and liver function without the need for repeated blood draws.

The new platform uses tiny microneedles that painlessly sample fluid one millimeter below the skin. Earlier microneedle systems struggled with weak signals and abrasion damage, but the UCLA design improves both sensitivity and durability. In rat studies, the sensor operated continuously for six days while tracking drug concentrations over time. These measurements revealed how quickly the animals cleared medications, which allowed the researchers to detect impaired kidney and liver function. In some cases, the sensor identified early kidney injury before conventional blood tests showed any abnormality.

The technology builds on the success of continuous glucose monitors, which transformed diabetes care by providing real‑time molecular data. Extending this approach to other molecules has been difficult because many exist at far lower concentrations than glucose. The UCLA system overcomes this challenge by improving signal quality and resistance to friction inside tissue. This makes continuous monitoring of drug levels and organ function more feasible for long‑term use.

By measuring how quickly drugs are cleared, the sensor can alert clinicians to early signs of organ decline and support more precise dosing decisions. This capability could be especially important for medications that place stress on the kidneys or liver. The researchers also note that the platform could be adapted to monitor additional health‑related molecules over time, expanding the role of wearable sensors in personalized medicine.